Clinical Trial Update: PErioperative CISGEM + Rilvegostomig in High-Risk Resectable Intra Hepatic CholangioCarcinoma [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating preoperative CISGEM (cisplatin + gemcitabine) plus Rilvegostomig for high-risk resectable intrahepatic cholangiocarcinoma; t…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Intrahepatic Cholangiocarcinoma

Drugs mentioned

• CISGEM (cisplatin + gemcitabine)
• Rilvegostomig (rilvegostomig)

Snippet

Sponsor: Federation Francophone de Cancerologie Digestive | Conditions: Intrahepatic Cholangiocarcinoma (Icc) | Phase 2 | Status: NOT_YET_RECRUITING